Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-01-31

Study Completion Date

2006-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this pilot study is to evaluate the improvement in social function following therapy with venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine. An additional purpose of this pilot study is to obtain the tolerability of using venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Evaluating Venlafaxine ER in Adults With Panic Disorder

NCT00038896

Panic Disorder

COMPLETED PHASE3

Study Evaluating Venlafaxine ER in Patients With Panic Disorder

NCT00044772

Panic Disorder

COMPLETED PHASE3

Effectiveness of Long-Term Versus Short-Term Treatment of Generalized Anxiety Disorder With Venlafaxine XR

NCT00183274

Anxiety Disorders

COMPLETED PHASE4

A Combination Therapy In Patients With Social Anxiety Disorder

NCT00403962

Social Phobia

COMPLETED PHASE2

Comparison of Pregabalin Versus Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder

NCT00151450

Anxiety

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Panic Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VENLAFAXINE

Intervention Type DRUG

Paroxetine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Meet DSM IV criteria for Panic Disorder (with or without agoraphobia) for at least 3 months before study day 1.
* Have a minimum of 8 full-symptom panic attacks during the 4 weeks before the screening visit.
* Provide a written informed consent

Exclusion Criteria

* Treatment with Venlafaxine within 6 months of study day 1, as well Paroxetine
* Known hypersensitivity to Venlafaxine or related compounds as well to Paroxetine.
* Psychopharmacologic drugs within 14 days of study day 1

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No